PureTech Health (LON:PRTC) Trading Up 14.2% - Time to Buy?

Key Points

• PureTech Health's share price surged by 14.2% during mid-day trading, reaching a high of GBX 123.80 ($1.67) as trading volume increased to about 9 million shares, marking a 1,053% rise from the average daily volume.
• The company has a market cap of £293.65 million, a PE ratio of 714.71, and a debt-to-equity ratio of 45.82, indicating potential concerns about debt levels in relation to equity.
• Insider activity was noted as Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1, showcasing ongoing confidence by corporate insiders in the company's future.

PureTech Health plc (LON:PRTC - Get Free Report) was up 14.2% on Friday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares were traded during mid-day trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Up 4.2%

The firm has a market capitalization of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The stock has a fifty day moving average of GBX 129.46 and a two-hundred day moving average of GBX 129.72. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51.

Insiders Place Their Bets

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the company's stock in a transaction that occurred on Thursday, July 3rd. The shares were acquired at an average price of GBX 1 per share, with a total value of £1,677.39. Insiders own 13.13% of the company's stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.